사람 혈장 중 페니토인 분석 및 생체이용률시험 |
강혜정1, 이혜자1, 남권호1, 운여민2, 강희경1, 유은숙1 |
1제주대학교 의과대학 약리학교실 2제주대학교 의과대학 진단검사의학교실 및 의과학연구소 |
Studies on The Plasma Analysis and Bioavailability of Phenytoin in Human |
Hae Jung Kang1, Hae Ja Lee1, Kweon Ho Nam1, Yeo Min Yoon2, Hee Kyeong Kang1, Eun Sook Yoo1 |
1Departments of Pharmacology, College of Medicine , Cheju National University, Jeju 690-756, Korea 2Departments of Laboratory Medicine, College of Medicine and Institute of Medical Science, Cheju National University, Jeju 690-756, Korea |
Correspondence:
Eun Sook Yoo, Email: eunsyoo@cheju.ac.kr |
|
Abstract |
A developed assay method to evaluate the pharmacokinetics of phenytoin in human plasma was investigated by reverse-phase HPLC-UV. We found the analytic condition that separate phenytoin from internal standard (triamcinolone acetonide) in human plasma sample at the wavelength of 225 nm. Proteins of the plasma samples were removed enough by using 0.1 N HC1. Mobile phase is consisted of buffer (pH3.0):CH3CN (65:35), and retention time of phenytoin is 8.2 min at a flow rate of 0.9 ml/min.. Tlie fundamental parameters such as linearity, accuracy, precision for this bioanalytical method validation were suitable to pharmacokinetic study and bioequvalence test. Eight volunteers in lasting were administered single dose of 100 mg of phenytoin (one tablet) orally together with 240 ml water for pharmacokinetic studies. The maximum concentration (0.82 ㎍/ml) of phenytoin was attained at 6.63 hour after dosing. T1/2 and AUC were 14.88 hr and 25.181 ㎍hr/ml respectively. According to our study, the accurate analysis for phenytoin achieved and the proposed guidance can be applied to pharmacokinetic study and bioequivalence test in human. |
Key Words:
Phenytoin; bioavailability; pharmacokinetics; HPLC; human plasma |
|